SMS Pharmaceuticals Limited — Important, 31-05-2025: General Updates

SMS Pharmaceuticals has announced a board meeting to approve the financial results for the quarter and half-year. FY25 revenue climbed 10% YoY to ₹783 Cr, supported by volume growth and a 43% QoQ Q4 rebound. EBITDA margin rose 132 bps to 18%, aided by backward integration, while PAT jumped 39% to ₹69 Cr. A ₹250 Cr capex is planned for capacity expansion and new product/contract manufacturing. The company cleared the USFDA inspection at its Hyderabad plant and plans to add 8-10 new products within 12-18 months.